Effects of glucagon-like peptide 1 on the hepatic glucose metabolism

Hormone and Metabolic Research

Volumn 36, Issue 11-12, 2004, Pages 837-841

  D'Alessio, D ^a   Vahl, T ^a   Prigeon, R ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Diabetes; GLP 1; Glycogen; Hepatic glucose production; Incretin

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

BLOOD GLUCOSE MONITORING; DIET RESTRICTION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLYCOGEN SYNTHESIS; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; LIVER CELL; LIVER METABOLISM; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; REVIEW;

ANIMALS; DOGS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLYCOGEN; HEPATOCYTES; HUMANS; INSULIN; LIVER; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 12244303683     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-826172     Document Type: Review

References (54)

1. D'Alessio DA, Vahl TP. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004; 286: E882-E890
2. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996; 271: E458-E464
3. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab 2004; 287: E75-E81
4. Nishizawa M, Moore MC, Shiota M, Gustavson SM, Snead WL, Neal DW, Cherrington AD. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Am J Physiol Endocrinol Metab 2003; 284: E1027-E1036
5. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913
6. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A 1992; 89: 8641-8645
7. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, Schuit F. Expression and functional activity of glucagon, glucagon-like peptide 1, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996; 45: 257-261
8. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide 1 receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 1997; 46: 785-791
9. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ. Effect of glucagon-like peptide-1(proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism: Clinical and Experimental 1994; 43: 104-108
10. Van Dijk G, Lindskog S, Holst JJ, Steffens AB, Ahren B. Effects of glucagon-like peptide-1 on glucose turnover in rats. Am J Physiol 1996; 270: E1015-E1021
11. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994; 134: 2156-2164
12. Yamato E, Ikegami H, Takekawa K, Fujisawa T, Nakagawa Y, Hamada Y, Ueda H, Ogihara T. Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1). Horm Metab Res 1997; 29: 56-59
13. Villanueva-Penacarrillo ML, Delgado E, Trapote MA, Alcantara A, Clemente F, Luque MA, Perea A, Valverde I. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 1995; 146: 183-189
14. Wheeler MB, Lu M, Dillon JS, Leng X-H, Chen C, Boyd AE. Functional expression of the rat glucagon-like peptide-1 receptor, evidence for coupling to both adenyl cyclase and phospholipase-C. Endocrinology 1993; 133: 57-62
15. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-2978
16. Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998; 141: 179-186
17. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S, Giacca A. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 1999; 48: 1045-1053
18. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide 1: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Letters 1995; 358: 219-224
19. Wei Y, Mojsov S. Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 1996; 157: 355-357
20. Ikezawa Y, Yamatani K, Ohnuma H, Daimon M, Manaka H, Sasaki H. Glucagon-like peptide-1 inhibits glucagon-induced glycogenolysis in perivenous hepatocytes specifically. Regul Pept 2003; 111: 207-210
21. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, Perea A, Villanueva-Penacarrillo ML. Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 1994; 349: 313-316
22. Alcantara AI, Morales M, Delgado E, Lopez-Delgado MI, Clemente F, Luque MA, Malaisse WJ, Valverde I, Villanueva-Penacarrillo ML. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys 1997; 341: 1-7
23. Morales M, Lopez-Delgado MI, Alcantara A, Luque MA, Clemente F, Marquez L, Puente J, Vinambres C, Malaisse WJ, Villanueva-Penacarrillo ML, Valverde I. Preserved GLP-1 effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 1997; 46: 1264-1269
24. Lopez-Delgado MI, Morales M, Villanueva-Penacarrillo ML, Malaisse WJ, Valverde I. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. Endocrinology 1998; 139: 2811-2817
25. Marquez L, Trapote MA, Luque MA, Valverde I, Villanueva-Penacarrillo ML. Inositolphosphoglycans possibly mediate the effects of glucagon-like peptide-1(7-36)amide on rat liver and adipose tissue. Cell Biochem Funct 1998; 16: 51-56
26. Redondo A, Trigo MV, Acitores A, Valverde I, Villanueva-Penacarrillo ML. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 2003; 204: 43-50
27. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42: 856-864
28. Nakagawa Y, Kawai K, Suzuki H, Ohashi S, Yamashita K. Glucagon-like peptide-1(7-36) amide and glycogen synthesis in the liver. Diabetologia 1996; 39: 1241-1242
29. Freyse EJ, Becher T, El-Hag O, Knospe S, Goke B, Fischer U. Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs. Diabetes 1997; 46: 824-828
30. Freyse EJ, Knospe S, Becher T, El HagO, Goke B, Fischer U. Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. Metabolism 1999; 48: 134-137
31. Prigeon RL, Quddusi S, Paty B, D'Alessio DA. Suppression of endogenous glucose production by glucagon-like peptide 1 independent of islet hormones: An extrapancreatic effect of an incretin hormone. Am J Physiol Endocrinol Metab 2003; 28: 28
32. Toft-Nielsen M, Madsbad S, Holst JJ. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 1996; 45: 552-556
33. Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 1997; 160: 413-422
34. Orskov L, Holst JJ, Moller N, Alberti KGMM, Schmitz O. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 1996; 39: 1227-1232
35. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 2000; 49: 611-617
36. Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like Peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002; 87: 3768-3773
37. Shalev A, Ninnis R, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on glucose kinetics during somatostatin-induced suppression of insulin secretion in healthy men. Horm Res 1998; 49: 221-225
38. Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk WF, Rizza RA. Effect of enteral vs. parenteral glucose delivery on initial splanchnic glucose uptake in nondiabetic humans. Am J Physiol Endocrinol Metab 2002; 283: E259-E266
39. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. American Journal of Physiology 1996; 271: E808-E813
40. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst 1996; 61: 149-154
41. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1449-R1454
42. Burcelin R, da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 2001; 50: 1720-1728
43. Han VKM, Hynes MA, Jin C, Towle AC, Lauder JM, Lund PK. Cellular localization of proglucagon/glucagon-like peptide 1 messenger RNAs in rat brain. Journal of Neuroscience 1986; 16: 97-107
44. Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM, Lund PK. Distribution of glucagonlike peptide 1 (GLP-1), glucagon, and glicentin in the rat brain: An immunocytochemical study. J Comp Neurol 1988; 271: 519-532
45. Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC, D'Alessio D. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride [In Process Citation]. J Neurosci 2000; 20: 1616-1621
46. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, Nakayama K, Uchida K. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004; 110: 36-43
47. Vahl TP, Elfers E, Woods SC, Seeley RJ, D'Alessio D. Signaling from GLP-1 receptors in the hepatic portal bed is required for oral glucose tolerance. Diabetes 2003; 52: A78
48. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997; 40: 597-601
49. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997; 273: G920-G927
50. Prechtl JC, Powley TL. A light and electron microscopic examination of the vagal hepatic branch of the rat. Anat Embryol (Berl) 1987; 176: 115-126
51. Berthoud HR, Kressel M, Neuhuber WL. An anterograde tracing study of the vagal innervation of rat liver, portal vein and biliary system. Anat Embryol (Berl) 1992; 186: 431-442
52. Niijima A. Glucose-sensitive afferent nerve fibres in the hepatic branch of the vagus nerve in the guinea-pig. Journal of Physiology 1982; 332: 315-323
53. Nakabayashi H, Niijima A, Kurata Y, Usukura N, Takeda R. Somatostatin-sensitive neural system in the liver. Neuroscience Letters 1986; 67: 78-81
54. Boyle PJ, Liggett SB, Shah SD, Cryer PE. Direct muscarinic cholinergic inhibition of hepatic glucose production in humans. J Clin Invest 1988; 82: 445-449